Kisspeptin-10 vs Thymosin Alpha-1
Specialty
Kisspeptin-10
C-terminal decapeptide of kisspeptin, the upstream regulator of GnRH release via the KISS1R receptor.
Specialty
Thymosin Alpha-1
28-amino-acid thymic peptide studied for Toll-like receptor signaling and T-cell maturation.
Side by side
| Dimension | Kisspeptin-10 | Thymosin Alpha-1 |
|---|---|---|
| Molecular weight A 2.4× difference in mass — these are not comparable on a milligram-for-milligram basis. | 1302.45 g/mol | 3108.3 g/mol |
| Size class | short peptide | mid-length peptide |
| CAS number | 374675-21-5 | 62304-98-7 |
| Research area | specialty | specialty |
| Sequence | Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2 | Not published as a linear sequence |
| Available sizes | 5mg | 10mg |
| Entry price | $39 | $59 |
| Cost per mg | $7.80 | $5.90 |
Mechanism
Kisspeptin-10
Kisspeptin-10 is the shortest fully active fragment of kisspeptin, the product of the KISS1 gene. Its discovery reframed reproductive neuroendocrinology: kisspeptin signaling through KISS1R (GPR54) sits upstream of GnRH neurons and is now understood as a gatekeeper of the reproductive axis. Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, which is the genetic evidence anchoring the pathway.
Thymosin Alpha-1
Thymosin alpha-1 is a 28-amino-acid N-terminally acetylated peptide originally isolated from thymic tissue. It is among the better-characterized immunomodulatory peptides, with published mechanism centering on TLR2 and TLR9 signaling in dendritic cells and downstream effects on T-cell differentiation. Unlike much of this catalog, it has an established clinical literature under the name thymalfasin.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Kisspeptin-10
Evidence base: solid receptor pharmacology with an established genetic basis. The desensitisation result under continuous exposure is specific, published, and frequently overlooked. Non-reproductive mechanisms are emerging and less replicated.
Full research reference →Thymosin Alpha-1
Evidence base: the largest and highest-quality in this catalogue after the incretin compounds. Multiple approved indications and a 2025 randomised phase 3 sepsis trial. The modulatory mechanism is context-dependent and correspondingly harder to interpret than a simple agonist relationship.
Full research reference →Research applications
Kisspeptin-10
- KISS1R (GPR54) receptor binding and activation assays
- GnRH pulse generation studies in hypothalamic models
- Reproductive axis and puberty-onset research
- Metastasis suppression studies (the original KISS1 context)
Thymosin Alpha-1
- TLR2 and TLR9 signaling assays in dendritic cell culture
- T-cell maturation and differentiation studies
- Cytokine profiling (IL-2, IFN-γ) in immune models
- Vaccine adjuvant research
Common questions
What is the difference between Kisspeptin-10 and Thymosin Alpha-1?
Kisspeptin-10 is c-terminal decapeptide of kisspeptin, the upstream regulator of GnRH release via the KISS1R receptor. Thymosin Alpha-1 is 28-amino-acid thymic peptide studied for Toll-like receptor signaling and T-cell maturation. They differ in molecular weight (1302.45 vs 3108.3 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Kisspeptin-10 or Thymosin Alpha-1?
Thymosin Alpha-1 is lower at approximately $5.90 per milligram at its best tier, against $7.80 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Kisspeptin-10 and Thymosin Alpha-1 be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Kisspeptin-10 and Thymosin Alpha-1 be stored?
Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days. For Thymosin Alpha-1: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Kisspeptin-10 — Evidence base: solid receptor pharmacology with an established genetic basis. The desensitisation result under continuous exposure is specific, published, and frequently overlooked. Non-reproductive mechanisms are emerging and less replicated. Thymosin Alpha-1 — Evidence base: the largest and highest-quality in this catalogue after the incretin compounds. Multiple approved indications and a 2025 randomised phase 3 sepsis trial. The modulatory mechanism is context-dependent and correspondingly harder to interpret than a simple agonist relationship.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.